Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
复制标题
DOI:
10.1172/jci.insight.88766
复制
发表时间:
2016-10-20
期刊:
影响因子:
8
通讯作者:
Semple RK
中科院分区:
文献类型:
--
作者:
Huang-Doran I;Tomlinson P;Payne F;Gast A;Sleigh A;Bottomley W;Harris J;Daly A;Rocha N;Rudge S;Clark J;Kwok A;Romeo S;McCann E;Müksch B;Dattani M;Zucchini S;Wakelam M;Foukas LC;Savage DB;Murphy R;O'Rahilly S;Barroso I;Semple RK
Obesity-related insulin resistance is associated with fatty liver, dyslipidemia, and low plasma adiponectin. Insulin resistance due to insulin receptor (INSR) dysfunction is associated with none of these, but when due to dysfunction of the downstream kinase AKT2 phenocopies obesity-related insulin resistance. We report 5 patients with SHORT syndrome and C-terminal mutations in PIK3R1, encoding the p85α/p55α/p50α subunits of PI3K, which act between INSR and AKT in insulin signaling. Four of 5 patients had extreme insulin resistance without dyslipidemia or hepatic steatosis. In 3 of these 4, plasma adiponectin was preserved, as in insulin receptor dysfunction. The fourth patient and her healthy mother had low plasma adiponectin associated with a potentially novel mutation, p.Asp231Ala, in adiponectin itself. Cells studied from one patient with the p.Tyr657X PIK3R1 mutation expressed abundant truncated PIK3R1 products and showed severely reduced insulin-stimulated association of mutant but not WT p85α with IRS1, but normal downstream signaling. In 3T3-L1 preadipocytes, mutant p85α overexpression attenuated insulin-induced AKT phosphorylation and adipocyte differentiation. Thus, PIK3R1 C-terminal mutations impair insulin signaling only in some cellular contexts and produce a subphenotype of insulin resistance resembling INSR dysfunction but unlike AKT2 dysfunction, implicating PI3K in the pathogenesis of key components of the metabolic syndrome. C-terminal mutations in human PIK3R1 are associated with severe insulin resistance in the absence of dyslipidemia or hepatic steatosis.
登录
查看更多内容
影响因子:
15.9
作者:
Cusi, K;Maezono, K;Mandarino, LJ
通讯作者:
Mandarino, LJ
影响因子:
13.5
作者:
Browning, JD;Szczepaniak, LS;Hobbs, HH
通讯作者:
Hobbs, HH
影响因子:
9.8
作者:
Dyment, David A.;Smith, Amanda C.;Innes, A. Micheil
通讯作者:
Innes, A. Micheil
影响因子:
5.3
作者:
Chen, D;Mauvais-Jarvis, F;Kahn, CR
通讯作者:
Kahn, CR
影响因子:
48
作者:
Clark, Jonathan;Anderson, Karen E.;Juvin, Veronique;Smith, Trevor S.;Karpe, Fredrik;Wakelam, Michael J. O.;Stephens, Len R.;Hawkins, Phillip T.
通讯作者:
Hawkins, Phillip T.